• Lymphocytes
  • The characterization of tumor-associated antigens recognized by human T lymphocytes in a major histocompatibility complex (MHC)-restricted fashion has opened new possibilities for immunotherapeutic approaches to the treatment of human cancers. (uni-regensburg.de)
  • melanoma
  • This clone recognized all melanoma cell lines tested and, to a lower extent, melanocytes, in the context of human histocompatibility leukocyte antigen A2 (HLA-A2), but it did not recognize other tumor cell types. (nih.gov)
  • The gene coding for the antigen recognized by this clone was identified by the screening of a melanoma complementary DNA expression library. (nih.gov)
  • This antigen is overexpressed in melanomas, compared with other cancer cell lines and healthy tissues, and was thus called melanoma-overexpressed antigen (meloe). (nih.gov)
  • Overall, our results suggest that this new antigen is involved in immunosurveillance and, thus, represents an attractive target for immunotherapy protocols of melanoma. (nih.gov)
  • Proteins
  • IKK/NF-κB Transcription Factor Pathway: CD79 and other proteins, microsignalosomes, go to activate PLC-γ after antigen recognition by the BCR and before it goes to associate into the c-SMAC. (wikipedia.org)
  • human
  • First discovered in 1979, EpCAM was initially described as a dominant surface antigen on human colon carcinoma. (wikipedia.org)
  • autoantibody
  • A neuronal lineage marker can be a neuronal antigen that is recognized by an autoantibody for example Hu, which is highly restricted to neuronal nuclei. (wikipedia.org)
  • Systemic lupus erythematosus is associated with increased autoantibody titers against calreticulin, but calreticulin is not a Ro/SS-A antigen. (wikipedia.org)
  • marker
  • Additionally, EpCAM has oncogenic potential via its capacity to upregulate c-myc, e-fabp, and cyclins A & E. Since EpCAM is expressed exclusively in epithelia and epithelial-derived neoplasms, EpCAM can be used as diagnostic marker for various cancers. (wikipedia.org)
  • therapy
  • The Food and Drug Administration (FDA) is announcing that it is codifying the reclassification of tumor-associated antigen immunological test systems intended as an aid in monitoring patients for disease progression or response to therapy or for the detection of recurrent or residual disease from class III (premarket approval) to class II (special controls). (biomedsearch.com)
  • latter
  • The pro-thymocytes differentiate into common thymocytes, and then into medullary thymocytes, and it is at this latter stage that CD3 antigen begins to migrate to the cell membrane. (wikipedia.org)
  • common
  • In 2013, two groups detected calreticulin mutations in a majority of JAK2-negative/MPL-negative patients with essential thrombocythemia and primary myelofibrosis, which makes CALR mutations the second most common in myeloproliferative neoplasms. (wikipedia.org)
  • class
  • After the β2-microglobulin binds to the peptide-loading complex (PLC), calreticulin (along with ERp57) takes over the job of chaperoning the MHC class I protein while the tapasin links the complex to the transporter associated with antigen processing (TAP) complex. (wikipedia.org)
  • This association prepares the MHC class I for binding an antigen for presentation on the cell surface. (wikipedia.org)
  • test
  • reclassification of tumor-associated antigen immunological test system--FDA. (biomedsearch.com)
  • Among 800 pools of 100 pcDNA tested, one plasmid pool proved positive in this test, and the individual plasmid coding for the recognized antigen was recovered from it after a cloning step. (nih.gov)
  • levels
  • However, continued exposure to antigen through those low levels of immunoglobulin is important, as it partly determines the cell's lifespan. (wikipedia.org)
  • patients
  • A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. (wikipedia.org)